Phase I, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5300, Administered IM Followed by Electroporation in Healthy Volunteers
Latest Information Update: 04 Jul 2020
At a glance
- Drugs GLS 5300 (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions; First in man
- Sponsors GeneOne Life Science
- 25 Jul 2019 According to an Inovio Pharmaceuticals media release, positive results from this trial were published in The Lancet Infectious Diseases.
- 12 Mar 2019 According to Inovio Pharmaceuticals media release, Inovio expects to have clinical data from several Phase 1 vaccine programs published multiple publications in 2019: Ebola vaccine; MERS vaccine; HIV; and ZIka vaccine study in Puerto Rico.
- 31 Jul 2018 Status changed from active, no longer recruiting to completed.
Most Recent Events
Trial Overview
Purpose
This study will evaluate the safety of GLS-5300 at one of three dose levels following a three-injection vaccination regimen followed by electroporation. The study will also assess immune responses over a 1 year period with respect to the generation of antibody and cellular responses.
Primary Endpoints
Mean change from baseline in safety laboratory measures
safety_issue: Yes
time_frame: Day0 through Week 60
Incidence of solicited adverse events after vaccination
safety_issue: Yes
time_frame: Day0 through Week 60
Incidence of unsolicited adverse events after vaccination
safety_issue: Yes
time_frame: Day0 through Week 60
Incidence of serious adverse events
safety_issue: Yes
time_frame: Day0 through Week 60
Other Endpoints
Binding antibody response to S protein
safety_issue: No
time_frame: Day0 through Week 60 following the first dose
Neutralizing antibody response to S protein
safety_issue: No
time_frame: Day0 through Week 60 following the first dose
T cell response
safety_issue: No
time_frame: Day 0 through Week 60 following the first dose [1]
Diseases Treated
Indication | Qualifiers | Patient Segments |
---|---|---|
Middle East respiratory syndrome coronavirus | prevention | - |
Subjects
- Subject Type patients
-
Number
Planned: 75
Actual: 75
- Sex male & female
- Age Group 18-50 years; adult
Patient Inclusion Criteria
1. Age 18-50 years; military, civilian, male and female. 2. Able to provide consent to participate and having signed an Informed Consent Form. 3. Able and willing to comply with all study procedures. 4. Women of child-bearing potential agree to remain sexually abstinent, use medically effective contraception (oral contraception, barrier methods, spermicide, etc.) or have a partner who is sterile from enrollment to 3 months following the last injection, or have a partner who is unable to induce pregnancy. 5. Sexually active men who are considered sexually fertile must agree to use either a barrier method of contraception during the study, and agree to continue the use for at least 3 months following the last injection, or have a partner who is permanently sterile or unable to become pregnant; 6. Normal screening ECG or screening ECG with no clinically significant findings; 7. Screening labs must be within normal limits or have only Grade 0-1 findings; 8. No history of clinically significant immunosuppressive or autoimmune disease. 9. Not currently or within the previous 4 weeks taking immunosuppressive agents (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or corticosteroids at a dose less than 20 mg/day). 10. Willing to allow storage and future use of samples for MERS CoV related research
Patient Exclusion Criteria
1. Administration of an investigational compound either currently or within 30 days of first dose; 2. Previous receipt of an investigational product for the treatment or prevention of MERS CoV except if participant is verified to have received placebo; 3. Previous infection with MERS CoV as assessed by self report and solicited exposure history; 4. Administration of any vaccine within 4 weeks of first dose; 5. A BMI greater than or equal to 35; 6. Administration of any monoclonal or polyclonal antibody product within 4 weeks of the first dose; 7. Administration of any blood product within 3 months of first dose; 8. Pregnancy or breast feeding or have plans to become pregnant during the course of the study; 9. History of positive serologic test for HIV, hepatitis B surface antigen (HBsAg); or any potentially communicable infectious disease as determined by the Principal Investigator or Medical Monitor; 10. Positive serologic test for hepatitis C (exception: successful treatment with confirmation of sustained virologic response); 11. Baseline evidence of kidney disease as measured by creatinine greater than 1.5 (CKD Stage II or greater); 12. Baseline screening lab(s) with Grade 2 or higher abnormality; 13. Chronic liver disease or cirrhosis; 14. Immunosuppressive illness including hematologic malignancy, history of solid organ or bone marrow transplantation; 15. Current or anticipated concomitant immunosuppressive therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or corticosteroids at a dose less than 20 mg/day); 16. Current or anticipated treatment with TNF-α inhibitors such as infliximab, adalimumab, etanercept; 17. Prior major surgery or any radiation therapy within 4 weeks of group assignment; 18. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome; 19. Presence of a cardiac pacemaker or automatic implantable cardioverter defibrillator (AICD); 20. Metal implants within 20 cm of the planned site(s) of injection; 21. Presence of keloid scar formation or hypertrophic scar as a clinically significant medical condition at the planned site(s) of injection. 22. Prisoner or participants who are compulsorily detained (involuntary incarceration) for treatment of either a physical or psychiatric illness; 23. Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements or assessment of immunologic endpoints; or 24. Tattoos covering the injection site area h 25. Any illness or condition that in the opinion of the investigator may affect the safety of the participant or the evaluation of any study endpoint.
Trial Details
Identifiers
Identifier | Owner |
---|---|
NCT02670187 | ClinicalTrials.gov: US National Institutes of Health |
WRAIR2274 | - |
Organisations
- Sponsors GeneOne Life Science
- Affiliations GeneOne Life Science; Inovio Pharmaceuticals
Trial Dates
-
Initiation Dates
Planned : 01 Dec 2015
Actual : 01 Feb 2016
-
Primary Completion Dates
Planned : 01 May 2017
Actual : 01 May 2017
-
End Dates
Planned : 01 Sep 2017
Actual : 01 Sep 2017
Other Details
- Design open; parallel; prospective
- Phase of Trial Phase I
- Location USA
- Focus Adverse reactions; First in man
Interventions
Drugs | Route | Formulation |
---|---|---|
GLS 5300Primary Drug | Intramuscular | Injection |
GLS-5300
GLS-5300 at 0.67 mg DNA/dose
Biological: GLS-5300
GLS-5300 at 2 mg DNA/dose
GLS-5300 at 2 mg DNA/dose
Biological: GLS-5300
GLS-5300 at 6 mg DNA/dose
GLS-5300 at 6 mg DNA/dose
Biological: GLS-5300
Results
Adverse events
Interim results from phase I trial demonstrated that administration of INO-4800 was generally safe and well tolerated in healthy participants for 8 weeks. Six reported mild (all Grade 1 in severity), transient adverse events, such as minor injection site reactions, related to vaccine dose. No serious adverse events were reported.
Interim results from the phase I trial demonstrated that the vaccine was well tolerated and no significant safety concerns were noted to date [2] .
Immunogenicity
Updated data from a phase I trial demonstrated that antibody responses by ELISA in 94% of subjects at week 14 (two weeks post-third dose). Also, broad-based t cell responses were observed in 88% of participants. No statistically significant dose-dependent differences in antibody response rates (91%, 95%, and 95% at doses of 0.67, 2, and 6 mg, respectively) were reported. Durable antibody responses to the vaccine were also maintained through 60 weeks following dosing. Earlier results demonstrated that after a three dose vaccine regimen with GLS 5300 intramuscular, high levels of binding antibodies were measured in 92% (57 of 62) of evaluated subjects. Earlier reported interim results showed that single or two doses of the vaccine generated a robust antibody response in 84% or 44% of evaluated participants, respectively. Significant antigen-specific cytotoxic T-lymphocyte (CTL) responses were observed and 98% of subjects generated an antibody and/or T cell response against the MERS vaccine. Results were presented from the 75 healthy volunteers [3] [4] [2] .
Updated results from phase I trial demonstrated T cell response and INO 4800 induced neutralising antibodies against UK, Brazilian and South African strains. The results showed that INO 4800 induced a robust T cell response against all spike protein variants tested. In addition, vaccine also demonstrated similar levels of neutralizing activity against the UK (B.1.1.7), South Africa (B.1.351) and Brazilian (P.1) variants as those against the original strain. Furthermore, INO-4800 generated robust neutralizing antibodies at levels against Brazilian variant which were comparable to those against the Wuhan strain. Earlier interim results from the trial demonstrated that 100% of participants achieved immunological response. 95% of vaccinated participants had overall seroconversion after two vaccine doses. Nearly 90% of vaccinated participants generated strong T cell responses. One participant in the 1.0 mg dose cohort and two participants in the 2.0 mg dose cohort were excluded in the immune analyses as they tested positive for COVID-19 immune responses at study entry, indicating prior infection.
Publications
-
Inovio Pharmaceuticals. Inovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases. Media-Rel 2017;.
Media Release -
Inovio Pharmaceuticals. Inovios MERS Vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study. Media-Rel 2018;.
Media Release -
Inovio Pharmaceuticals. Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS. Media-Rel 2018;.
Media Release -
Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet-Infect-Dis 2019;19(9):1013-1022.
PubMed | CrossRef Fulltext
Trial Centres
Investigators
Investigator | Centre Name | Trial Centre Country |
---|---|---|
Amy Castellano
1-301-319-9850
show details
amy.r.castellano.ctr@mail.mil |
-
|
|
Kayvon Modjarrad, MD, PhD
1-301-500-3623
show details
Usarmy.detrick.medcom-wrair.mbx.clinical-trials@mail.mil |
Walter Reed Army Institute of Research (WRAIR) |
-
|
Centres
Centre Name | Location | Trial Centre Country |
---|---|---|
- |
-
|
-
|
GeneOne Life Science, Inc. |
-
|
-
|
Inovio Pharmaceuticals |
-
|
-
|
Walter Reed Army Institute of Research (WRAIR) |
-
|
-
|
Walter Reed Institute of Research | Silver Spring, Maryland | USA |
Trial History
Event Date | Event Type | Comment |
---|---|---|
01 Sep 2019 | Results | Results published in The Lancet Infectious Diseases Updated 04 Jul 2020 |
25 Jul 2019 | Results | According to an Inovio Pharmaceuticals media release, positive results from this trial were published in The Lancet Infectious Diseases. Updated 29 Jul 2019 |
12 Mar 2019 | Other trial event | According to Inovio Pharmaceuticals media release, Inovio expects to have clinical data from several Phase 1 vaccine programs published multiple publications in 2019: Ebola vaccine; MERS vaccine; HIV; and ZIka vaccine study in Puerto Rico. Updated 19 Mar 2019 |
11 Jan 2019 | Other trial event | Last checked against ClinicalTrials.gov record. Updated 11 Jan 2019 |
31 Jul 2018 | Status change - completed | Status changed from active, no longer recruiting to completed. Updated 11 Aug 2018 |
27 Jun 2018 | Results | According to an Inovio Pharmaceuticals media release, data from this trial was presented at the WHO-IVI Joint Symposium for MERS-CoV Vaccine Development. Updated 04 Jul 2018 |
27 Jun 2018 | Results | Results presented in the Inovio Pharmaceuticals media release. Updated 04 Jul 2018 |
11 Apr 2018 | Results | Results published in the Inovio Pharmaceuticals media release. Updated 16 Apr 2018 |
04 Jan 2018 | Other trial event | According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Jul 2016). Updated 04 Jan 2018 |
23 Feb 2017 | Results | According to an Inovio Pharmaceuticals media release, positive Clinical Data was presented at the Coalition for Epidemic Preparedness Innovation (CEPI) 1st Scientific Meeting. Updated 08 Mar 2017 |
23 Feb 2017 | Interim results | Interim results published in the Inovio Pharmaceuticals Media Release. Updated 03 Mar 2017 |
06 Dec 2016 | Other trial event | According to an Inovio Pharmaceuticals media release, interim data from this study is expected in early 2017 and publish the full data set in peer reviewed journals. Updated 13 Dec 2016 |
08 Aug 2016 | Other trial event | According to an Inovio Pharmaceuticals media release, the company expects to report interim immune response and safety data from this trial in the fourth quarter of 2016. Updated 31 Aug 2016 |
26 Jul 2016 | Status change - active, no longer recruiting | Status changed from recruiting to active, no longer recruiting. Updated 29 Jul 2016 |
17 Feb 2016 | Other trial event | New source identified and integrated (ClinicalTrials.gov NCT02670187). Updated 17 Feb 2016 |
28 Jan 2016 | Status change - recruiting | According to an Inovio Pharmaceuticals media release, status changed from planning to recruiting. Updated 29 Jan 2016 |
19 Nov 2015 | Other trial event | According to GeneOne Life Science media release, the U.S. FDA has announced the approval of this trial as a first-in-human study. Updated 23 Nov 2015 |
21 Oct 2015 | New trial record | New trial record Updated 21 Oct 2015 |
19 Oct 2015 | Other trial event | According to a company media release, GeneOne Life Science plans to initiate this study before the end of 2015. Updated 21 Oct 2015 |
Table of Contents
References
-
ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2023;.
Available from: URL: http://clinicaltrials.gov -
Inovio Pharmaceuticals. Inovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases. Media-Rel 2017;.
Media Release -
Inovio Pharmaceuticals. Inovio's Positive First-in-Human MERS Vaccine Results Published in The Lancet Infectious Diseases. Media-Rel 2019;.
Media Release -
Inovio Pharmaceuticals. Inovios MERS Vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study. Media-Rel 2018;.
Media Release -
Inovio Pharmaceuticals. Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute. Media-Rel 2016;.
Media Release -
GeneOne Life Science. GeneOne Life Science and Inovio Pharmaceuticals MERS Vaccine Approved for First-in-Human Study. Media-Rel 2015;.
Media Release -
Inovio Pharmaceuticals. Inovio Pharmaceuticals and GeneOne Life Science Initiate Patient Recruitment for MERS Vaccine Trial. Media-Rel 2016;.
Media Release -
Inovio Pharmaceuticals. Inovio Pharmaceuticals Reports 2018 Fourth Quarter and Year-End Financial Results. Media-Rel 2019;.
Media Release -
Inovio Pharmaceuticals. Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS. Media-Rel 2018;.
Media Release -
Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet-Infect-Dis 2019;19(9):1013-1022.
PubMed | CrossRef Fulltext -
GeneOne Life Science. Inovio and Partner Advance MERS Vaccine. Media-Rel 2015;.
Media Release -
Inovio Pharmaceuticals. Inovio Pharmaceuticals Reports 2016 Second Quarter Financial Results. Media-Rel 2016;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG